Home » Posts tagged with » SARS-CoV-2
AstraZeneca to advance AZD7442 into phase 3 Covid-19 trials

AstraZeneca to advance AZD7442 into phase 3 Covid-19 trials

AstraZeneca said that AZD7442, which is being developed for the prevention and treatment of Covid-19, will move into two phase 3 clinical trials. AZD7442 is a combination of a couple of monoclonal antibodies (mAbs) extracted from convalescent patients with SARS-CoV-2 infection. It will be assessed in more than 6,000 participants at sites in and outside […]

Novavax begins phase 3 trial of NVX-CoV2373 COVID-19 vaccine candidate

Novavax has initiated its first phase 3 clinical trial to assess the efficacy, safety, and immunogenicity of its NVX-CoV2373 COVID-19 vaccine candidate. The US vaccine development company is carrying out the late-stage trial in the UK in partnership with the UK government’s Vaccines Taskforce. The phase 3 trial of NVX-CoV2373 will aim to enroll and […]

Continue reading …
Janssen Covid-19 vaccine candidate Ad26.COV2.S bags $1bn deal from US govt

Johnson & Johnson (J&J) said that its subsidiary Janssen Pharmaceutical has agreed to manufacture and supply 100 million doses of its SARS-CoV-2 investigational vaccine Ad26.COV2.S to the US government, in a deal worth more than $1 billion. The Janssen Covid-19 vaccine candidate will be supplied either after approval by the US Food and Drug Administration […]

Continue reading …
Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FDB

Novavax has signed an agreement with FUJIFILM Diosynth Biotechnologies (FDB), a US-based contract development and manufacturing organization (CDMO), for the manufacturing of bulk drug substance for NVX-CoV2373, the former’s COVID-19 vaccine candidate. FUJIFILM Diosynth Biotechnologies’ facility in Morrisville, North Carolina has started production of the first batch of NVX-CoV2373. The arrangement between the two firms […]

Continue reading …
BNT162 COVID-19 vaccine candidate : US govt signs $2bn supply deal with Pfizer and BioNTech

Pfizer and BioNTech have bagged a $1.95 billion deal with the US government for supplying 100 million doses of their jointly developed BNT162 COVID-19 vaccine candidate. Recently, the two pharma companies were granted the fast track designation from the US Food and Drug Administration (FDA) for BNT162b1 and BNT162b1 vaccines, which are two of the […]

Continue reading …
COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response

COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine (AZD1222) to be well tolerated besides generating strong responses in all evaluated participants against the COVID-19 causing SARS-CoV-2 virus. The early-stage COVID-19 vaccine trial is being led by Oxford University, […]

Continue reading …
BNT162b1 and BNT162b2 Covid-19 vaccine candidates get FDA fast track status

Pfizer and BioNTech said that BNT162b1 and BNT162b2, two vaccine candidates developed to give protection against the SARS-CoV-2 virus have been given the fast track designation from the USFood and Drug Administration (FDA). The two vaccine candidates are part of the four investigational vaccine candidates that are being jointly developed by the companies under their […]

Continue reading …
Gilead Sciences announces Veklury EU approval for COVID-19 treatment

Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 infection, the virus behind COVID-19. According to the US pharma company, the conditional marketing authorization for Veklury was given in the interest of public health because of the coronavirus pandemic […]

Continue reading …
Noxopharm launches NOXCOVID-1 clinical trial of Veyonda across Europe

Noxopharm, an Australian clinical-stage pharma company, has started the phase 1 NOXCOVID-1 clinical trial for Veyonda in Europe to evaluate the anti-cancer drug candidate as a potential treatment for cytokine storm and septic shock in COVID-19 patients. With a capability to inhibit cGAS-STING signalling, Veyonda can potentially block the start of the cytokine storm which […]

Continue reading …
Imperial College begins human trial of coronavirus vaccine candidate COVAC1

Imperial College London said that it has dosed the first healthy volunteer with its COVAC1 coronavirus vaccine candidate, which has been developed using the new self-amplifying RNA (saRNA) technology. The university claimed that the COVID-19 vaccine candidate has gone through rigorous pre-clinical safety tests, and in animal studies, it has been demonstrated to be safe, […]

Continue reading …
Page 1 of 212